Treating Hepatitis C in Methadone Patients: With Planning, it Works! Patricia Perkins, MS, MPH Independent Healthcare Consultant Community Advisory Board.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.
Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.
Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Out of Sight, Out of Time: Injection Drug Users, Hepatitis C, and HIV Policy Daniel Raymond Hepatitis C Policy Analyst Harm Reduction Coalition
Patrizia FARCI. Hepatitis Delta Virus Hepatitis B surface antigen (HBsAg) HDV RNA genome Hepatitis delta antigen (HDAg) 36 nm From HDV: From HBV: From.
Management of Hepatitis C in Alcohol and Other Drug Services Greg Dore Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Hepatitis web study Hepatitis web study WINR Study Flat versus Weight-Based Ribavirin Dosing Phase 3 Treatment Naïve, Chronic HCV Jacobson IM, et. al.
Treatment of HCV infection among active IDUs Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Epidemiology and Management of HCV in Injection Drug Users Patricia Perkins, MS, MPH Independent Healthcare Consultant San Francisco & Los Angeles, CA.
Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year , ,000 Persons.
Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Psychosocial support for IDUs and effects on HCV treatment Bernd Schulte.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Hepatitis-2015 Orlando, USA July
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,
How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.
Hepatitis C When, how and which patients should be treated Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.
Pennsylvania: The State of HCV 2015
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.
S L I D E 0 Enhanced Uptake of Hepatitis C Treatment in an Opioid Treatment Program in the Direct Acting Antiviral Era Jenna Butner MD 1,2, Julia Shi MD.
Integrating Hepatitis C and Drug Treatment in a Community-Based Setting Diana L. Sylvestre, MD O.A.S.I.S. Organization to Achieve Solutions in Substance-Abuse.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
What is the contribution of alcohol to liver disease in the hepatitis C infected population. The epidemiological evidence Hamish Innes Research Fellow.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Maria Buti,1 Yoav Lurie,2 Natalia G. Zakharova,3 Natalia P. Blokhina,4 Andrzej Horban,5 Gerlinde Teuber,6 Christoph Sarrazin,6 Ligita Balciuniene,7 Saya.
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
National Hepatitis C Database
129 patients with chronic hepatitis C
TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
Phase 3 Treatment-Naïve and Treatment-Experienced
GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b
Phase 3 Treatment-Naïve and Treatment-Experienced
Clinical outcome after SVR: Veterans Affairs
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Starting Strong: Initial Evaluation of the Patient With HCV
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
Boceprevir in Treatment Naive SPRINT-2
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Impact of metabolic risk factors on HCC
Telaprevir in Treatment Experienced GT-1 PROVE3
Phase 3 Treatment-Naïve and Treatment-Experienced
Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study
Presentation transcript:

Treating Hepatitis C in Methadone Patients: With Planning, it Works! Patricia Perkins, MS, MPH Independent Healthcare Consultant Community Advisory Board Member Organization to Achieve Solutions in Substance- Abuse (O.A.S.I.S.)

IFN alfa-2b/RBV: Summary of Predictive Factors for a SVR Weight > 75 kg Weight  75 kg High Fibrosis Low Fibrosis Male Female Age > 40 Age  40 High HCV RNA Low HCV RNA Genotype 1 Genotype 2 or 3 Increasing usefulness in predicting sustained response % Sustained Virologic Response McHutchison JG et al. Semin Liver Dis. 1999;19(suppl 1):63.

Questions: some of the many… Does methadone use affect HCV treatment: dosing levels? Does psychiatric disease in IDUs affect HCV treatment? Should all patients be on SSRI’s? Does length of sobriety affect HCV treatment? Does alcohol use [during tx] affect HCV treatment? Does illicit drug use [during tx] affect HCV treatment?

O.A.S.I.S., Oakland, CA Medical Care FOR IDUs Addresses special needs of IDU – Distrust of authority – High prevalence of psychiatric illness – Psychosocial problems – Limited or Inconsistent Social Support – High level of misinformation about HCV and most other medical illnesses

Group Treatment Model: One Stop Shopping Education Peer support Medical monitoring

O.A.S.I.S. HCV Patients >900 patients screened to date: from 5-8 area MMTs and other persons with DU histories – All with Liver Function Tests – Most with PCR (polymerase chain reaction) and/or genotype >100 treated

O.A.S.I.S. HCV Patient Demographics 51% male vs 66% 47 yr vs 42 yr 58% Caucasian vs 95% 29 yr infected vs 17 yr 61% psychiatric dx 29% cirrhosis vs 4%

Histology in Treated MMT

ALT vs Liver Fibrosis

Interim Interferon/Ribavirin Treatment Results n=67 n=59

OASIS non-MMT vs OASIS MMT n=67 n=17n=59 n=22

The Impact of Psychiatric Disease in MMT p=0.46 n=22 n=41 n=37 n=26

The Impact of Alcohol Use on HCV Treatment p=0.46 n=57 n=45 n=12 n=47 n=13 n=45 n=12

Impact of Drug Use During HCV Treatment n=57 n=6 n=37 n=17n=4 n=57 n=17 n=40 n=20 n=39 n=37 n=20

Impact of Illicit Drug Quantity on HCV Outcomes n=57 n=6 n=37 n=17n=4 n=7 n=40 n=6 n=4 n=7 n=39 n=7 n=5 n=7 n=37 n=7 n=5 n=7

Impact of Pretreatment Drug Sobriety n=11 n=9 n=12 n=25 n=39 n=9 n=12 n=37 n=8 n=12

Treatment Results: No Preexisting Psych, No Drugs, No Alcohol n=13 n=12

Early Conclusions: HCV treatment in MMT is safe, tolerable, and efficacious. Psychiatric illness, intermittent drug use, and alcohol use have a modest negative impact on treatment outcomes in MMT. Regular drug use may impact substantially on virologic outcomes, and therefore relapse to drug use during HCV treatment should lead to aggressive substance abuse intervention.

Acknowledgements O.A.S.I.S. staff, Board, CAB & volunteers ***Schering Oncology-Biotech Participating MMT clinics – BAART – SAACS – 14 th St. Clinic – HAART

Knowledge is power. Saber es el poder. Please Join our Fight! Future Presentations will continue to be posted on our website: